Results of conservative management of clinically localized prostate cancer - PubMed (original) (raw)
Meta-Analysis
. 1994 Jan 27;330(4):242-8.
doi: 10.1056/NEJM199401273300403.
Affiliations
- PMID: 8272085
- DOI: 10.1056/NEJM199401273300403
Free article
Meta-Analysis
Results of conservative management of clinically localized prostate cancer
G W Chodak et al. N Engl J Med. 1994.
Free article
Abstract
Background: The selection of treatment for patients with localized prostate cancer requires reliable information about the outcome of conservative management. Previous studies of this question are generally considered unreliable because they were uncontrolled and nonrandomized.
Methods: We performed a pooled analysis of 828 case records from six nonrandomized studies, published since 1985, of men treated conservatively (with observation and delayed hormone therapy but no radical surgery or irradiation) for clinically localized prostate cancer. A Cox regression analysis was performed to determine which factors influenced survival among patients who did not die of causes other than prostate cancer (disease-specific survival). Kaplan-Meier curves for overall and metastasis-free survival among such patients were compared with use of the log-rank method and the Mantel-Haenszel test.
Results: Factors that had a significant effect on disease-specific survival were grade 3 tumors (risk ratio, 10.04), residence in Israel (risk ratio, 2.48) or New York (risk ratio, 0.37), and age under 61 years (risk ratio, 0.32). Ten years after diagnosis, disease-specific survival (with data on men who died from causes other than prostate cancer censored) was 87 percent for men with grade 1 or 2 tumors and 34 percent for those with grade 3 tumors; metastasis-free survival among men who had not died of other causes was 81 percent for grade 1, 58 percent for grade 2, and 26 percent for grade 3 disease. These findings were not affected by the inclusion of men who had early-stage cancer, were older, had worse-than-average health, or underwent delayed radiation therapy or radical prostatectomy.
Conclusions: The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who have an average life expectancy of 10 years or less. New treatment strategies are needed for men with grade 3 prostate cancer.
Comment in
- Conservative management of prostate cancer.
Catalona WJ. Catalona WJ. N Engl J Med. 1994 Jun 23;330(25):1830-1; author reply 1831-2. N Engl J Med. 1994. PMID: 8190170 No abstract available. - Conservative management of prostate cancer.
Scardino PT, Beck JR, Miles BJ. Scardino PT, et al. N Engl J Med. 1994 Jun 23;330(25):1831; author reply 1831-2. N Engl J Med. 1994. PMID: 8190171 No abstract available.
Similar articles
- Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators. Kawakami J, et al. Cancer. 2006 Apr 15;106(8):1708-14. doi: 10.1002/cncr.21799. Cancer. 2006. PMID: 16544313 - Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Hoffman RM, et al. Am J Med. 2006 May;119(5):418-25. doi: 10.1016/j.amjmed.2005.06.072. Am J Med. 2006. PMID: 16651054 - Should we treat localized prostate cancer? An opinion.
Menon M, Parulkar BG, Baker S. Menon M, et al. Urology. 1995 Nov;46(5):607-16. doi: 10.1016/S0090-4295(99)80289-1. Urology. 1995. PMID: 7495109 - [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M, Villers A, Richaud P, Prapotnich D, Ruffion A, Grosclaude P. Soulié M, et al. Prog Urol. 2001 Dec;11(6):1195-204. Prog Urol. 2001. PMID: 11859652 Review. French. - Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.
Hoffman KE. Hoffman KE. Semin Radiat Oncol. 2012 Oct;22(4):284-94. doi: 10.1016/j.semradonc.2012.05.005. Semin Radiat Oncol. 2012. PMID: 22985811 Review.
Cited by
- Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.
Kato T, Hirama H, Kamoto T, Goto T, Fujimoto H, Sakamoto S, Shinohara N, Egawa S, Kouguchi D, Nakayama M, Hashine K, Shimizu N, Inoue K, Habuchi T, Hioka T, Shiraishi T, Sugimoto M, Kakehi Y. Kato T, et al. Int J Clin Oncol. 2024 Oct;29(10):1557-1563. doi: 10.1007/s10147-024-02590-4. Epub 2024 Aug 1. Int J Clin Oncol. 2024. PMID: 39085727 - Health care delivery system contributions to management of newly diagnosed prostate cancer.
Krampe N, Kaufman SR, Oerline MK, Hill D, Caram MEV, Shahinian VB, Hollenbeck BK, Maganty A. Krampe N, et al. Cancer Med. 2023 Aug;12(16):17346-17355. doi: 10.1002/cam4.6349. Epub 2023 Jul 20. Cancer Med. 2023. PMID: 37475511 Free PMC article. - Active Surveillance for Prostate Cancer: Past, Current, and Future Trends.
de Vos II, Luiting HB, Roobol MJ. de Vos II, et al. J Pers Med. 2023 Apr 3;13(4):629. doi: 10.3390/jpm13040629. J Pers Med. 2023. PMID: 37109015 Free PMC article. Review. - Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Wade J, Noble S, Garfield K, Young G, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Blazeby J, Bryant R, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Powell P, Prescott S, Rosario D, Rowe E, Neal D. Hamdy FC, et al. Health Technol Assess. 2020 Aug;24(37):1-176. doi: 10.3310/hta24370. Health Technol Assess. 2020. PMID: 32773013 Free PMC article. Clinical Trial. - Long-term oncologic outcomes after radical prostatectomy in clinically localized prostate cancer: 10-year follow-up in Korea.
Suh J, Jung JH, Jeong CW, Lee SE, Lee E, Ku JH, Kim HH, Kwak C. Suh J, et al. Investig Clin Urol. 2020 May;61(3):269-276. doi: 10.4111/icu.2020.61.3.269. Epub 2020 Apr 21. Investig Clin Urol. 2020. PMID: 32377602 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical